Drugs for disorders of the alimentary tract or the digestive system (A61P1)

A   Human necessities(308424)
A61P1                 Drugs for disorders of the alimentary tract or the digestive system(7081)
External application means for chronic dermatosis treatment, and method for its production // 2628535
FIELD: medicine.SUBSTANCE: invention can be used as a preventive and therapeutic agent with anti-inflammatory and antibacterial properties, intended for external use, for treatment of all kinds of chronic dermatoses: dermatitis, neurodermatitis, furunculosis, eczema, fungal diseases, parasitic skin diseases, acne, and method for its production. The external agent for treatment of chronic dermatitis in the form of an aqueous suspension of mercuric monochloride is prepared by a process comprising premixing of powdered mercury monochloride with nitric acid at the following ratio of components, wt %: mercury monochloride 0.3-0.6; nitric acid 0.6-1.0, at a temperature of 70-90°C, stirring for 1 hour. Then the obtained solution is mixed with water of high mineralization from the "Belaya Gorka" mineral source to 100 wt %. At that, the pH of the obtained suspension is adjusted to 1-2 with nitric acid.EFFECT: increased efficiency of treatment.2 cl, 7 ex
Pyperidinyl naphthyluxic acids // 2628083
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of formula (I): , as well as to pharmaceutically acceptable salts, pharmaceutical compositions and application thereof.EFFECT: new compounds that are CRTH2 receptor antagonists have been obtained that can be useful for respiratory diseases treatment or prevention.20 cl, 2 tbl, 37 ex
Hinuclidine ethers of 1-azaheterocylic acetic acid as antimuscarine means, method for their production and their drug compositions // 2628082
FIELD: pharmacology.SUBSTANCE: invention relates to formula compounds, where A can be a single bond, a double bond, O, S, NR3, C(R3)R4, CO, C(O)N(R3), N(R3)C(O) and C(R3)-(CH2)-C(R4); m is an integer from 1 to 4; N is 0 or an integer from 1 to 4; R1 is selected from the group consisting of phenyl and 5-member heteroaryl containing one S heteroatom optionally substituted by one or more substituents selected from the group consisting of halogen atoms, (C1-C6)alkyl and (C1-C6)alkoxy; X is a physiologically acceptable anion; R2 is a group of the formula (Y), where p is 0 or an integer from 1 to 4; Q is 0 or an integer from 1 to 4; P is absent or selected from the group consisting of CO, N(R3)C(O) and C(O)N(R3); W is selected from the group consisting of H, (C1-C10)alkoxyl, phenyl, heteroaryl optionally substituted with one or more substituents selected from the group consisting of halogen atoms, OH, oxo (=O), CO2R3, (C1-C6)alkyl, (C1-C6)alkoxyl and phenyl; wherein heteroaryl is a mono- or bicyclic ring system having from 5 to 9 ring atoms and from 1 to 3 heteroatoms selected from N, O and S; R3 and R4 are independently selected from the group consisting of H, halogen atoms, CONH2, (C1-C6)alkyl, (C1-C6)alkanoyl and (C3-C8)cycloalkyl, as selective M3 receptor antagonists, to a method for their preparation, to compositions containing them, and to their therapeutic use for treatment of a respiratory disease such as asthma and chronic obstructive pulmonary disease (COPD).EFFECT: increased composition application efficiency.14 cl, 2 tbl, 34 ex
Compound as wnt signal inhibitor, its compositions and application // 2627712
FIELD: pharmacology.SUBSTANCE: invention relates to a heterocyclic compound of the general formula (I) or an N-oxide thereof, wherein X1, X2, X3 and X4 independently represent CR4 or N, where 0 or 1 of X1-X4 can be N; Y1, Y2 and Y3 are hydrogen; R1 is selected from hydrogen, , C6 aryl, 6-member heterocycloalkyl containing 2 heteroatoms selected from N and O, and 5- or 6-member heteroaryl containing 1-4 heteroatoms selected from N, O and S, wherein each of C6 aryl, 6-member heterocycloalkyl and 5- or 6-member heteroaryl may be optionally substituted with one R4; R2 is selected from hydrogen, halogen, C1-6 alkyl, , C6 aryl and 6-member heteroaryl containing 1 to 2 N atoms, where each of C6 aryl and 6-member heteroaryl may be optionally substituted with one R4. If X5 is N, R2 is selected from halogen, C1-6 alkyl, , C6 aryl and 6-member heteroaryl containing 1 to 2 N atoms, where each of C6 aryl, and 6-member heteroaryl may be optionally substituted with one R4; each R4 Is independently selected from hydrogen, halogen, cyano, oxo, C1-6 alkoxy, -C(O)OR5, -C(O)R5, C1-6 alkyl. Moreover , C1-6 alkyl may be optionally substituted with 1 to 3 substituents selected from halogen and cyano; R5 is C1-6 alkyl; and where the central structure of Formula I, limited by X5, X6, X7 and X8, is: or The invention also relates to particular compounds, a method for inhibiting the secretion of WNT signalling in a cell, use of a compound of formula (I), a method for treatment of a disorder mediated by WNT. .EFFECT: new heterocyclic compounds have been obtained that are useful for treatment of cancer, fibrosis and osteoarthritis.22 cl
Sulfonamide compounds and their use as tnap inhibitors // 2627701
FIELD: chemistry.SUBSTANCE: invention relates to compounds of Formula I: wherein: Y1 is a bond and Y2 is -N(R6)-; L1 and L2 are each a bond; X1 is =N- or =C(R2)-; X2 is =N- or =C(R3)-; R1 and R4 are independently selected from the group consisting of -F, -Cl, -Br, -CN, -C(O)N(R7)-R8, -C(O)-O-R9, methyl, -OMe, -OCF3, optionally substituted phenyl and optionally substituted 5- or 6-membered heteroaryl; R2, R3 and R5 are hydrogen; R6 is hydrogen; R7 is hydrogen and R8 is selected from hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl or optionally substituted phenyl; either R7 and R8 together with the nitrogen atom to which they are attached form an optionally substituted heterocycloamino which is an optionally substituted pyrrolidine, an optionally substituted piperidine, an optionally substituted morpholine or an optionally substituted piperazine; R9 is selected from hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl or optionally substituted phenyl; A is selected from the group consisting of -C(O)-N(R7)-R8 or -C(O)-O-R9, or A is , R12 and R13 are independently selected from the group consisting of hydrogen, halogen, -CN, -OH, -C(O)-O-R19, optionally substituted C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl optionally substituted with C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, optionally substituted phenyl and optionally substituted 5- or 6-membered heteroaryl, R19 is selected from the group consisting of hydrogen, optionally substituted C1-C4 lkila, C1-C4 haloalkyl, optionally substituted C3-C6 cycloalkyl and optionally substituted phenyl; and R15 represents hydrogen or C1-C4 alkyl; Wherein the substituted group is substituted by -CO2H, nitrile, hydroxyl, C1-C4 alkyl, C1-C4 alkoxy, phenyl, C3-C6 cycloalkyl or diC1-C4 alkylamine, which modulate TNAP activity.EFFECT: improved properties of compounds.14 cl, 1 tbl, 12 ex
Compounds of pyridazinamide and their use as synthetic syneckinasis inhibitors (syk) // 2627661
FIELD: chemistry.SUBSTANCE: invention relates to novel pyridazinamides of the formula I , where all variable substituents are defined in the claims, and their pharmaceutically acceptable salts, as well as a pharmaceutical composition based on them.EFFECT: compounds of the formula are SYK inhibitors and are useful for the treatment of autoimmune and inflammatory diseases.10 cl, 1 tbl, 43 ex
Polybacterial drug with advantages for health: with antioxidant effect, decreased cholesterol concentration, anti-inflammatory and immuno-modulating effect, and release of bioactive peptides inhibiting angiotensin-converting enzyme // 2627651
FIELD: biotechnology.SUBSTANCE: group of inventions refers to polybacterial probiotic drug including new strains of lactic acid bacteria Lactobacillus gasseri 7/12 NBIMCC No. 8720, Lactobacillus plantarum F12 NBIMCC No. 8722 and Lactobacillus helveticus A1, NBIMCC No. 8721, which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity. The group of inventions also refers to the use of drug as a probiotic agent, as well as an agent which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity.EFFECT: food additives, food and functional products, pharmaceutical preparations that include this drug, have a beneficial effect on the health of people and animals.9 cl, 8 dwg, 15 tbl
Short antimicrobial lipopeptides // 2627648
FIELD: medicine.SUBSTANCE: invention relates to a method for mammal skin or mucosal tissue microbial infection treatment comprising administration of a therapeutically effective amount of a composition comprising at least one peptide of formula Pal-lipid-lysine-proline-NH2 or Pal-lipid-lysine-d-proline-NH2, and a pharmaceutically acceptable carrier for an effective amount of time to the infected area.EFFECT: invention provides treatment of mammal skin or mucosal tissue microbial infections.6 cl, 1 ex, 4 tbl
ethod for thermal treatment of residual area of fibrous capsule arising after liver echinococcectomy // 2627645
FIELD: medicine.SUBSTANCE: cyst contents are maximally aspirated, Furacilin solution heated to 50°C is poured into in the cavity along the trocar, after 15 minutes exposure the Furacilin solution from the cavity is maximally aspirated. The procedure is repeated twice, then a fibrous capsule is cut between two holders for visual inspection.EFFECT: due to the high temperature of the solution used, the invention has a bactericidal, hemolytic and biliary effect, prevents appearance of purulent and bile-purulent fistulas in the postoperative period, prevents bleeding and disease relapse, high temperature created in the cavity has a disastrous effect not only on the cavity parasites, but also on those migrated beyond the fibrous capsule.1 dwg,1 ex
eans for teeth hard tissue remineralization // 2627624
FIELD: medicine.SUBSTANCE: proposed means for teeth hard tissues remineralization contains a component of the intended use - hydroxyapatite with high degree of purification, particle size of 20×150 nm, and a basis of 1500 and 400 polyethylene oxides in the following ratio, wt %: hydroxyapatite - 7, PEO 1500 - 74.4, PEO 400 - 18.6.EFFECT: increased resistance, acid resistance of teeth hard tissues, decreased enamel solubility, activation of the remineralization process, reduction of hyperesthesia, prevention of caries development, prevention of caries progression, prolongation of the remineralization effect due to a prolonged contact of the remineralizing gel with the surface of teeth hard tissues.1 tbl, 2 ex, 8 dwg
Cosmetic means with mineral thermal water "dzhemukhskaya tselebnaya" // 2627619
FIELD: cosmetology.SUBSTANCE: cosmetic means for skin with mineral thermal water "Dzehmukhskaya tselebnaya", containing a thick licorice root extract dissolved in thermal water, silver sulfate, peppermint or lavender essential oil, at that "Dzehmukhskaya tselebnaya" medium-high mineralized thermal water with a standard content of biologically active boron 40-80 mg/dm3 in H3 BO3 acid and silicon 110-140 mg/dm3 in H2SiO3 acid and pH medium reaction of 6.5-7.0 is contained as the thermal water.EFFECT: cosmetic means has a tonic, moisturizing, softening and refreshing properties, it helps to eliminate disturbances in sebaceous glands secretion, skin texture.4 tbl
ethod for treatment of destructive chronic periodontitis using injection form of autological platelet plasma // 2627582
FIELD: medicine.SUBSTANCE: method includes instrumental processing using rotor instruments with an extension of the apical part of the channel to a diameter of at least 025 ar per ISO, conicity of at least 4%, drug treatment of the dental canals with passive ultrasonic irrigation and canal drying, temporary obturation of canals with calcium hydroxide with sealing under glass ionomer cement, general drug therapy. Drug treatment is carried out with a 17% solution of ethylenediaminetetraacetate and 1.5% sodium hypochlorite solution, after 12-24 hours after calcium hydroxide repfreshing, injections of platelet autoplasma (PAP) are made into soft tissues in the fistula area, if present, submucosally in the transitional fold, subperiosteally in the projection of the apexes involved in the pathological process of roots from the vestibular or palatal, lingual surfaces. At that, calcium hydroxide refreshing and PAP injection the root canals are carried out once or 2-3 times with an interval of 7-10 days, then canal obturation is effected by lateral or vertical condensation of gutta-percha and the epoxide-amine resin-based sealer.EFFECT: use of the invention provides relief of acute inflammatory process, reduction of treatment time, stimulation of bone tissue regeneration and replacement of a defect in a chronic inflammation focus by accelerating natural mechanisms of tissue regeneration due to platelet-derived growth factors.6 dwg, 2 ex

Pharmaceutical compositions comprising oligomeric lactic acid // 2627470
FIELD: pharmacology.SUBSTANCE: invention provides a composition comprising i) an oligomeric lactic acid of formula (I) wherein n is an integer from 2 to 20, 2 to 19, or 2 to 18, and wherein the content of the oligomeric lactic acid which is a trimer, i.e, HL3, which coefficient n is 2, is approx. 10 to approx. 20 wt % of the oligomeric lactic acid total weight. The average molecular weight Mn of the oligomeric lactic acid is approx. 200 to approx. 500, and ii) a mucoadhesive agent. The oligomeric lactic acid content is 20 to 80 wt % and mucoadhesive agent content is from 10 to 65 wt %.EFFECT: improved properties.17 cl, 11 ex, 25 tbl, 9 dwg
ethod for atrophic skin scars treatment // 2627468
FIELD: medicine.SUBSTANCE: fully straightened filtered radio waves of high frequency, obtained by the radio wave device Surgitron®, and an autologous platelet-rich plasma are used. At that, blood is taken from the peripheral vein of the patient into vacuum tubes. Blood is mixed with an anticoagulant. The blood mixture is then centrifuged with an anticoagulant for 4-6 minutes at a centrifuge rotation speed of 700-900 rpm. After that, the upper layer of the platelet-rich plasma is extracted into a separate tube and activated by calcium ions by addition of calcium gluconate. The activated platelet-rich plasma is placed into the syringe and injected intradermally into the scar. The injected region is then warmed up to 41-43°C by the Surgitron® radio wave device with Pelleve® ClideSafe electrodes or PelleFirm for at least 4 minutes.EFFECT: invention allows to shorten the time of scars treatment in patients.11 cl, 1 ex
edical adsorbent and method for its obtaining // 2627464
FIELD: medicine.SUBSTANCE: medical adsorbent contains activated carbon in the form of spherical pellets, obtained by carbonizing and activation of regenerated cellulose in a spherical shape, and having average pore diameter of 1.5 to 2.2 nm, specific BET surface area of 700 to 3000 m2/g, average particle size of 115 to 1002 mcm, oxide content of 0.05 meq/g or more on the surface, and packing density of 0.4 to 0.8 g/ml. Method for adsorbent production comprises the steps of: spherical viscose conversion into regenerated spherical cellulose in an acid precipitation bath, and carbonizing of the resulting regenerated spherical cellulose at a temperature of 300°C to 700°C under a nitrogen atmosphere, and then steam activation at a temperature of 750°C to 1000°C, acid cleaning and heat treatment at a temperature of 500°C to 800°C. It can be used as a therapeutic or prophylactic agent for kidney disease or liver disease for oral administration.EFFECT: adsorbent has low dosage and excellent adsorption capacity and selective adsorption of toxins, it can shorten the activation time, it is economical and environmentally friendly.6 cl, 6 ex, 3 tbl
ethod of prevention of respiratory diseases in group keeping of calves // 2627461
FIELD: veterinary medicine.SUBSTANCE: method of preventing respiratory diseases of calves includes the use of a medicinal product based on vegetable raw materials, is characterized by the fact that before the formation of groups at an early stage of cultivation, in group of animals the calves are given a mixture of infusions of motherwort and pion in a ratio of 2:1 with milk at a dose of 2.5-3 ml.EFFECT: method allows to successfully prevent respiratory diseases of calves, increases the safety of animals and shortens the duration of the disease.3 cl, 2 tbl, 1 ex
ethod of lichen planus treating // 2627456
FIELD: medicine.SUBSTANCE: invention can be used to treat lichen planus (LP). The method includes taking a patient of prednisolone in an average daily dosage (SDS) of 30 mg, hydroxychloroquine in the SSD of 400 mg, mebhydroline in a 200 mg SDO, 25 mg of hydroxysine, external betamethasone cream. In addition, the patient additionally takes Noophen in a dose of 250-500 mg, three times, after meals, with the first reception of Noophen preparation prescribed for 3 hours before a single daily session of TPP therapy with bipolar current in the 70 Hz mode, starting at a current of at least 2.0 MA, in each subsequent procedure the current is increased by 0.2-0.4 mA, under the control of the clinical effect and the patient's condition after each procedure, the procedure time is 30-40 min, the course is 6-12 procedures.EFFECT: use of the invention makes it possible to shorten the time of systemic and topical application of hormonal drugs, to achieve a longer remission; eliminate cosmetic defects, improve the quality of life of patients.2 ex
ethod of treatment of obstructive bronchitis in dogs // 2627446
FIELD: veterinary medicine.SUBSTANCE: method involves the treatment with Vasotop P, a course of 1-2 months. Treatment of obstructive bronchitis with bacterial, viral and parasitic etiology is carried out in two stages, including the use of immunostimulants in the first stage with the administration of etiotropic therapy with antibiotics and/or antiparasitic drugs; in the second stage, the use of bronchodilators with the simultaneous use of Vasotop P at a dose of 0.125 mg per 1 kg Mass of the animal, and in the presence of relapse - for life. In another embodiment, the method comprises using Veroshpiron in capsules at a dose of 100 mg per dog 20 kg Course 5-7 days; Vasotope P at a dose of 0.125 mg per 1 kg Weight of the animal, course 1-2 months, and at the terminal stage of life and Riboxin + glucose of 2.5 ml per dog 20 kg 1 time per day, 3 days, intravenously.EFFECT: highly effective treatment of dogs with obstructive bronchitis on the background of chronic cardiac and renal insufficiency.2 cl, 1 dwg, 1 ex
ethod for respiratory disorders syndrome prevention for newborns // 2627441
FIELD: medicine.SUBSTANCE: for prevention of respiratory disorders syndrome in newborns, the patients receive Dexamethazon intramuscularly, 8 mg №3 in 8:00 hours on 25(0)-27(6) week of pregnancy, the course is repeated in 7 days with the total dose of 48 mg.EFFECT: invention provides prolongation of pregnancy, complicated by fetal bladder prolapse or premature amniotic fluid discharge.2 dwg, 3 ex
Pharmaceutical preparation for rheumatological diseases treatment // 2627424
FIELD: pharmacology.SUBSTANCE: pharmaceutical preparation in the form of a solution for use in rheumatological diseases treatment contains a combination comprising sodium diclofenac or naproxen sodium, betamethasone sodium phosphate and hydroxy-cobalamin sulfate as active substances and benzyl alcohol, propylene glycol, sodium metabisulphite and water for injection as auxiliary components. A method for production of the preparation is described as well.EFFECT: stable, effective formulation with analgesic, anti-inflammatory and antineurotic effects.4 cl, 1 tbl, 4 ex
ethod of treatment of epithelial pilonidal sinus at the stage of abscedation // 2627350
FIELD: medicine.SUBSTANCE: after excision of the epithelial pilonidal sinus with the abscess shells, the wound bottom is treated for 5 minutes with a gas stream containing the nitrogen monoxide of the Plazon apparatus in the NO-therapy regime. After suturing and vacuum drainage of the wound along the Redon, deviating from the left and right edges of the ends of the postoperative wound, is administered subcutaneously in a solution of 32 units of lidase. 10 minutes after the administration of lidase, retreating to 1 cm from the place of its introduction, injected subcutaneously in a solution of 50 mcg of immunophane. The administration of lidase and immunofan is repeated after 48 hours in combination with the treatment of the postoperative wound for 5 minutes with nitrogen monoxide in the NO-therapy regimen.EFFECT: method allows to improve the results of treatment of patients with epithelial coccygeal circulation at the stage of abscess formation, due to the combined and complex effect on the wound and its area.3 dwg, 1 ex
Bicyclic heterocyclic derivatives, their production and application // 2627269
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of general formula (I) , as well as to a method for their preparation, pharmaceutical compositions based thereon, and their application.EFFECT: new compounds have been obtained that can be used to treat or prevent pathology for which it is necessary to inhibit the mTOR kinase.20 cl, 4 tbl, 30 ex
Aza-aryl-1-h-pyrazol-1-yl-sulphonamides // 2627268
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of formula (I) ,in which radicals and characters have values specified in the claims and their versions. The proposed compounds act as potent antagonists of CCR (9) receptor. Animal testing has shown that these compounds are useful for treatment of inflammation, disease with a hallmark for CCR (9). The compounds as a whole are arylsulfamide derivatives and are used in pharmaceutical compositions, methods for treatment of CCR (9) mediated diseases and as a control in assays for identification of CCR (9) antagonists.EFFECT: increased efficiency of compounds application.26 cl, 2 tbl, 33 ex

Glycosylated polypeptides and medicinal compositions containing these polypeptides // 2627184
FIELD: biotechnology.SUBSTANCE: glycosylated somatostatin analogs containing two or three glycosylated amino acids are obtained.EFFECT: invention allows to increase the stability of somatostatin analogues in blood in comparison with somatostatin.14 cl, 20 dwg, 10 tbl, 91 ex
ethod of treatment of central scrolleromy // 2627153
FIELD: medicine.SUBSTANCE: for the treatment of focal scleroderma, lesions are affected by low-energy laser radiation of the infrared range with a repetition rate of 1500 Hz, a pulse duration of 110-160 ns, a pulse power of 4-6 W/pulse, and 1-3 minutes per field. The total duration of exposure is no more than 15 minutes. Immediately before exposure to laser radiation on the scleroderma foci impose a gel for the body NOLLA naturelle®. In this case, exposure to laser radiation alternates every other day with paraffin applications on scleroderma foci, at a temperature of 48-52°C, time 20 minutes. The course of treatment is 8-10 complex procedures.EFFECT: method provides a multifactorial effect on all parts of metabolic processes in pathologically altered fibrotic dermal foci with a reduction in side effects and contraindications to the treatment.2 ex

Prodrug compositions with high degree of penetration based on peptides and related compounds // 2627065
FIELD: pharmacology.SUBSTANCE: invention relates to compositions with a high degree of penetration or prodrugs with a high degree of penetration based on a peptide or a peptide-related compound that contain a functional unit, a linker and a transport unit. The functional unit is covalently bound to the transport unit via the linker and comprises a peptide or peptide-related compound fragment. The transport unit comprises an amino group capable of being protonated. The linker comprises a bond capable of cleavage after composition penetration through a biological barrier.EFFECT: increased penetration.27 cl, 2 dwg, 16 tbl, 6 ex

1-phenyl-2-pyridinylalkyl alcohols derivatives as phosphodiesterase inhibitors // 2626956
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of general formula , where: R1 is selected from the group consisting of: methyl; trifluoromethyl; R2 is selected from the group consisting of: methyl optionally substituted with cyclopropyl; cyclopentyl; or R1 and R2, together with their interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (q) condensed with a phenyl group that carries -OR1 and -OR2 groups, where the asterisks indicate carbon atoms shared by such phenyl ring: , R19 is hydrogen; R3 is one or more substituents independently selected from halogen atoms; Z represents a -(CH2)n- group, where n is 0 or 1; A is a saturated and monocyclic (C3-C7) heterocycloalkylene group selected from the following list of di-radicals: , , , , , , , , , , where symbols [3] and [4] indicate the points of group A attachment to groups Z and K, respectively; K is selected from the group consisting of: -(CH2)mC(O)R4, where m can be 0 or 1; -C(O)(CH2)jR4, where j can be 1 or 2; -SO2(CH2)pR4, where p can be 0, 1 or 2; -(CH2)ySO2R4, where y can be 1 or 2; -(CH2)zR4, where z can be 1; and -C(O)(CH2)2SO2R4; R4 is a ring system which is a mono- or bicyclic ring which may be saturated, partially unsaturated or fully unsaturated, selected from phenyl, (C3-C8) cycloalkyl, (C3-C7) heterocycloalkyl where at least one ring carbon atom is replaced by a heteroatom selected from N, NH and O or heteroaryl, such ring is optionally substituted with one or more R5, which may be the same or different and which are independently selected from the group consisting of: (C1-C6) alkyl, optionally substituted with one or more groups independently selected from the list consisting of: -OH; (C3-C7) heterocycloalkyl(C1-C4)alkyl where at least one ring carbon atom is replaced by a heteroatom selected from N, NH, O; 5-6 member heteroaryl where at least one ring carbon atom is replaced by a heteroatom selected from N and O; -OR6 group, where R6 is selected from the group consisting of (C1-C6) haloalkyl; -SO2R7 group, where R7 is (C1-C4) alkyl; and methyl optionally substituted with one or more (C3-C7) cycloalkyls; halogen atoms; CN; NR8R9, where R8 and R9 are different or identical and independently selected from the group consisting of: H; (C1-C4) alkylen-NR13 R14, where R13 and R14 are different or identical and independently selected from the group consisting of: a (C1-C6) alkyl, or they form a saturated (C3-C7) heterocyclic ring together with the nitrogen atom to which they are attached; -SO2R15 group, where R15 is selected from the group consisting of: (C1-C4) alkyl; -C(O)OR17 group, where R17 is selected from the group consisting of: (C1-C6) alkyl; or they form, together with the nitrogen atom to which they are attached, a saturated or partially saturated heterocyclic ring which is optionally substituted by one or more (C1-C6) alkyl; (C1-C2) alkylene-NR8R9, as mentioned above; COR10, where R10 is (C1-C6) alkyl; oxo; -SO2R11, where R11 is (C1-C4) alkyl or NR8R9, where R8 and R9 are as above; -COOR12, where R12 is H, (C1-C4) alkyl or (C1-C4) alkylene-NR8R9, where R8 and R9 are as above; and -CONR8R9, where R8 and R9 are as above; where R6, R8, R9, R10, R11, R12, R13, R14, R15, R17 and R19 groups in each case may have the same or different value if more than one group is present; and their N-oxide derivatives on the pyridine ring or their pharmaceutically acceptable salts. The compound is a phosphodiesterase 4 (PDE4) enzyme inhibitors.EFFECT: improved properties.19 cl, 26 tbl, 36 ex
Adamantyl derivatives useful for treatment of jnk-mediated disorder // 2626890
FIELD: chemistry.SUBSTANCE: invention relates to the field of organic chemistry, namely to the heterocyclic compound of I formula or a pharmaceutically acceptable salt thereof, wherein R represents phenyl optionally substituted with one or more R'; R' is halo or methoxy; X represents CH; X1 represents C(=O)OCH3; Y represents N; Y1 It is OH, N(Y1')2, NHS(=O)2Y1', NHC(=O)Y1', NHC(=O)C(CH3)2OH or NHC(=O)C(CH3)2OC(=O)Y1'; each Y1' independently represents H, C1-6-alkyl or lower cycloalkyl; Y2 It is H. The invention also relates to formula I based on the compound of the pharmaceutical composition and the use thereof.EFFECT: new heterocyclic compounds useful for treating JNK-mediated disorder are obtained.12 cl, 5 tbl, 31 ex

ethods of production isoquinolinones and solid forms isoquinolinones // 2626883
FIELD: chemistry.SUBSTANCE: invention relates to new polymorphic forms of the compounds of formula (I), having inhibitory action against phosphoinositide 3-kinase (PI3K). The compounds may be used to treat cancer, such as leukemia, lymphoma, inflammatory disease and autoimmune disease. The polymorphic forms of the compound of formula (I) is the polymorphic form C of the hydrate of the compound of formula (I), which has characteristic peaks in the x-ray powder diffraction pattern (XRPD) 2θ=10.4°(±0.2°), 13.3°(±0.2°) and 24.3°(±0.2°); Polymorph A, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.6°(±0.2°), 12.2°(±0.2°), and 18.3°(±0.2°); Polymorph B, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=7.9°(±0.2°), 13.4°(±0.2°), and 23.4°(±0.2°); polymorphic form D, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=11.4°(±0.2°), 17.4°(±0.2°), and 22.9°(±0.2°); polymorphic form E, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=6.7°(±0.2°), 9.3°(±0.2°) and 24.4°(±0.2°); Polymorphic form F, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.6°(±0.2°), 17.3°(±0.2°), and 24.6°(±0.2°); Polymorphic form G which is the solvate of the tert-butyl methyl ether of the compound of formula (I) and has characteristic peaks in the powder XRPD pattern 2θ=6.7°(±0.2°), 9.5°(±0.2°) and 19.0°(±0.2°); Polymorphic form H, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=8.9°(±0.2°), 9.2°(±0.2°) and 14.1°(±0.2°); Polymorphic Form I, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.7°(±0.2°), 19.3°(±0.2°), and 24.5°(±0.2°), and the polymorphic form J, which has characteristic peaks in the X-ray powder diffraction pattern (XRPD) 2θ=9.1°(±0.2°), 17.3°(±0.2°) and 18.3°(±0.2°). The invention also relates to a process of preparing form C. For example, mentioned process comprising (i) exposure of the medium containing water, a composition comprising at least one polymorphic form, not a form of a compound of formula (I), for a period time sufficient for the transformation, preferably for 18-24 hours, at least 50% of the total amount of the polymorphic form (s) a non-form C; and (ii) recovering mentioned polymorph form C.EFFECT: high effectiveness of compounds.84 cl, 31 dwg, 16 tbl, 42 ex
Preparation for treatment of bony lumps, headaches and heartaches // 2626844
FIELD: pharmacology.SUBSTANCE: invention is a preparation for application to the skin surface for bony lumps, headaches and heartaches treatment, consisting of 5 ml of turpentine, 50 ml of 40% formalin, characterized by additional content of 96% ethyl alcohol solution in an amount of 45 ml. The proportions of constituents are given for 100 ml of the preparation.EFFECT: invention provides resorption of bony lumps, disappearance of pain in the heart and head areas, and also allows to do without surgical installation of plates for vertebrae fixation while infringing the nerve fibers as a result of their squeezing.5 ex
eans for polyps treatment in sinuses and prevention of their repeated growth, and method of its application // 2626829
FIELD: medicine.SUBSTANCE: method for polyps treatment in the sinuses is proposed. The method is characterized by application of aqueous solutions of acetic acid in concentrations of 3-6% as means or drug component for the treatment of polyps in the nose sinuses, and 1-2 drops of solution are injected into each sinus within 1-2 weeks, 3-5 times a day.EFFECT: improved safety and effectiveness of polyps treatment in the sinuses, prevention of repeated growth, reduced duration and costs of treatment.3 ex
ethod for hypertrophic gingivitis treatment in patients with non-removable orthodontic devices with application of injection form of autological platelet-rich plasma // 2626826
FIELD: medicine.SUBSTANCE: for conservative treatment of hypertrophic gingivitis in patients with non-removable orthodontic devices against the background of professional oral hygiene and topical application of chlorhexidine within 10 days, fraction of platelet-rich autologous plasma obtained from the supernatant space of tube after centrifugation is injected intrapapillary into the hypertrophic gingiva papillae, and the remaining fraction is introduced submucosally into the transitional fold in a total volume of 8-9 ml in the area of all teeth. The injection procedure is repeated after 7 days.EFFECT: method allows to shorten the treatment time, to stop the inflammatory process, to stimulate regeneration due to acceleration of its natural mechanisms due to the growth factors contained in platelets in the prevention of relapse.5 dwg, 1 tbl, 2 ex
ethod for prevention of periodontium inflammatory diseases in patients with non-removable orthodontic devices with application of injection form of autological platelet-rich plasma // 2626825
FIELD: medicine.SUBSTANCE: for prevention of inflammatory periodontal diseases in patients on orthodontic treatment with non-removable devices after the hardware professional oral cavity hygiene with local use of chlorhexidine for 7 days, autologous platelet plasma is injected submucosally into the transitional fold in a total volume of 8-9 ml in the region of all teeth. The procedure is repeated in the framework of supporting periodontal therapy at intervals of 4-6 months during orthodontic treatment and once in the retention period.EFFECT: method allows to prevent inflammatory complications from the periodontal tissues due to the acceleration of the natural tissue regeneration mechanisms.4 dwg, 1 tbl, 1 ex
eans for treatment of skin and mucosa diseases, for local use, which is anti-inflammatory, anti-bacterial, antiviral, wound-healung, anti-fungal // 2626673
FIELD: pharmacology.SUBSTANCE: means for skin and mucosa diseases treatment, which has anti-inflammatory, anti-bacterial, antiviral, wound-healing, anti-fungal activity, is a Gynura Procumbens leaf hydrolyte obtained by steam or water distillation of fresh or dry leaves of Gynura Procumbens at a fresh leaves and water ratio of 1:3-6 or at a dry leaves and water ratio of 1:30-60.EFFECT: means has a high efficiency for treatment of skin and mucosa diseases due to pronounced anti-inflammatory, anti-bacterial, antiviral, wound-healing, anti-fungal action.1 tbl, 13 ex
Drug for body soft tissue disorders treatment // 2626671
FIELD: medicine.SUBSTANCE: proposed drug has the form of a powder and contains a nitrogen-containing drug substance that generates nitrogen monoxide in the affected tissue, namely sodium nitrite or nitrofural or furazoline or furadonin or furagin or its potassium salt or metronidazole or nitroxoline, as well as cytochrome C, ascorbic acid or sodium ascorbate, zinc oxide, and auxiliary substances (starch or sodium salt of carboxymethyl cellulose, or hydroxypropyl cellulose or hydroxypropylcellulose) and talc.EFFECT: implementation of the invention allows to obtain a drug exhibiting high efficacy in treatment of long-lasting body soft tissue damages, including wounds, burns, trophic skin ulcers, pressure ulcers and other various skin lesions.3 cl, 3 tbl, 16 ex
ethod of treatment of posttraummatic fibrosive ankiloses of small juices of brush // 2626591
FIELD: medicine.SUBSTANCE: method includes the installation of an external fixation device (EFD) and the implementation of a stage distraction of the joint area up to 9 mm by 3 mm per day. In the formed cavity on the 3rd and 6th day after the AVF installation, 1.5-2 ml of plasma enriched with platelets (PRP) is injected, which amounts to 1,000,000-1200,000 cells. After the second injection, the EFD is dismantled and active rehabilitation treatment is carried out. The third injection of PRP is performed pararticularly on the 9th day.EFFECT: reducing the time to restore or improve the function of the fingers.1 ex, 5 dwg
ethod for treatment of hypercorrection arising in case of contour plastics by gels based on hyaluronic acid // 2626588
FIELD: medicine.SUBSTANCE: defect is localized by ultrasound. Correction is carried out in 2 stages. First, phonophoresis with 1% hydrocortisone ointment is applied to the corresponding corrected zone, daily for 4 minutes and for 6-10 sessions. After 3 weeks, ultrasound monitoring is performed. After that, also under the ultrasound control, "Longidaza" at a dose of 75-150 MU is injected into the areas of undissolved gel exceeding 3 mm in size, bypassing the adjacent vessels and nerves. After 2 weeks, a repeated control ultrasound is performed to confirm the absence of undissolved gel patches.EFFECT: method allows to obtain the desired aesthetic result, to shorten the period of medical and social rehabilitation.2 ex

New group of peptides for treatment of female sexual dysfunction // 2626002
FIELD: pharmacology.SUBSTANCE: peptides of general formula (I) are proposed: A-Thr-Lys-Hyp-B-C-D-X, where A is 0, Met, Met(O), Thr, Ala, His, Phe, Lys, Gly; B is 0, Gly, Asp, Trp, Gln, Asn, Tyr, Hyp, Arg; C is 0, Arg, Phe, Tyr, Gly, His, Hyp, Lys; D is 0, Val, Gly, Tyr, Trp, Phe, His; X is OH, OCH3, NH2; where 0 is the absence of amino acid residue, provided that if A≠0, then B, and/or C, and/or D≠0, if B≠0, then C and/or D≠0, excluding tetrapeptides, as well as peptides Phe-Thr-Lys-Hyp-Gly, Thr-Lys-Hyp-Hyp-Arg, Thr-Lys-Hyp-Arg-Gly. Pharmaceutical compositions containing these peptides and their application for treatment of women with a marked decrease in libido or with a complete lack of libido, with orgasmic dysfunction, sexual dysfunction not caused by organic disorders or diseases, HSDD, FSAD or FSIAD are also proposed.EFFECT: stimulated sexual properties and increased stability during storage.13 cl, 6 dwg, 4 tbl, 3 ex
Derivatives of 1,2,4-triazine-4-amine // 2625791
FIELD: pharmacology.SUBSTANCE: compounds of Iyd formula possess an inhibitory activity against A1 receptor or A2a receptor. In formula Iyd B represents "CyBB". "CyBB" represents phenyl optionally having one or more substituents R4c. R4b, R4b' and R4c are, in each case independently, a halogen atom. CN. C1-8 alkyl, which optionally bears one or more substituents selected from halogen atoms, OR5a; C3-8 cycloalkyl; Heta; OR8; N (R9f) (R9g); =O; rr2 is 0-1; and ss tt are, in each case independently, 0 or 1, provided that ss and tt can not simultaneously be equal to 0. L1 and L2 are both single bonds; R8 represents, in each case independently, C1-8 alkyl, which optionally bears one or more substituents selected from halogen atoms. Heta represents, independently in each case, 3-6-membered fully saturated heterocyclic ring which contains one or two heteroatoms selected from O and N. R5a, R9f, R9g are H in each case independently; C1-10 alkyl. The invention also relates to individual compounds, to use of a compound, a pharmaceutical composition and a process for preparing a compound of Iyd formula.EFFECT: new compounds with an inhibitory activity against A1 receptor or A2a receptor.12 cl, 7 ex
N-(pyrid-4-yl) amides and n-(pyrimidin-4-yl) amides and their pharmaceutical and cosmetic application // 2625789
FIELD: pharmacology.SUBSTANCE: invention relates to new N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides of formula (1) or their pharmaceutically acceptable salts having the properties of androgen receptor inhibitor (AR). The compounds can be used for pharmaceutical or cosmetic composition to treat androgen-dependent disease or disorder. These diseases include dermatological diseases or disorders such as diseases or disorders of sebaceous gland (glands); acne; hyperseborrhea; greasy skin; seborrheic dermatitis; hyperpilosity or hirsutism; atopic dermatitis or androgenic alopecia. In N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl) amides of formula (1) , R1 is C1-6 alkyl, C3-7cycloalkyl, C1-6alkyloxy, -S(O)m-C1-6alkyl, C1-6fluoroalkyl, C1-6fluoroalkyloxy, C1-6alkyl-OH, -(CH2)iC1-6alkyloxy, -(CH2)j1-O-C1-6fluoroalkyl, CORa, CN, NO2, NR5R6 or halogen atom; R2 ishydrogen atom, methyl, methoxy or bromine atom; R3 and R4 are the same or different and represent hydrogen atom, C1-12alkyl, C3-9cycloalkyl, C1-6fluoroalkyl, -C1-6alkyl-OH, -(CH2)p-C1-6alkyloxy, -(CH2)q-C3-9cycloalkyl, -(CH2)rC1-6fluoroalkyl, -(CH2)s-O-C1-6fluoroalkyl, phenyl, heteroaryl, heterocyclyl group, -(CH2)t-phenyl or -(CH2)v-heteroaryl, where each phenyl and heteroaryl are optionally substituted with 1-3 same or different groups of Rc; as well as R3 and R4 together with carbon atom carrying them can form C3-9cycloalkyl group or heterocyclyl group, such as tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydro-1-oxo-thiopyranyl or tetrahydro-1.1-dioxo-thiopyranyl; Rc is C1-6alkyl, C3-7cycloalkyl, C1-6alkiloxi, -S(O)u-C1-6alkyl, C1-6fluoroalkyl, C1-6fluoroalkyloxy, C1-6alkyl-OH, CORd, CN, NO2, NR9R10, OH or halogen atom; Ra and Rdare the same or different and represent C1-6alkyl, C1-6alkyloxy or NR7R8; R5, R6, R7, R8, R9 and R10 are the same or different and represent hydrogen atom, C1-6alkyl, C3-7cycloalkyl or -(CH2)w-C3-7cycloalkyl; as well as R5 and R6 together with nitrogen atom carrying them can form heterocyclyl group; as well as R7 and R8 together with nitrogen atom carrying them can form heterocyclyl group; as well as R9 and R10 together with nitrogen atom carrying them can form heterocyclyl group; i, j, p, q, r, s, t, v and w are different or the same and represent 1, 2 or 3; n and u are different or the same and represent 0, 2 or 2; and X represents CH or N.EFFECT: improved properties of compounds.22 cl, 4 tbl, 80 ex
eans for emergency voice recovery at flash aphonia // 2625766
FIELD: medicine.SUBSTANCE: invention is a means for emergency recovery of voice in sudden aphonia, intended for inhalation, comprising lidocaine hydrochloride in an amount of 1.2-1.5% by weight, sodium bicarbonate in an amount of 0.5% by weight and water doubly-modified - the rest, at pH 8.4 and osmotic activity of 280-330 mOsmol/l of water.EFFECT: invention provides an emergency recovery of the suddenly lost voice, reduces the symptoms of inflammation of the vocal cords, has an anesthetic effect on the larynx, has a sedative effect without irritating, cauterizing and toxic action.1 cl
Application of pyrazole derivative in treatment of acute attacks of chronic obstructive pulmonary disease // 2625762
FIELD: pharmacology.SUBSTANCE: 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof are applied. Application of a single dose of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methyl-benzamide or a pharmaceutically acceptable derivative thereof, using 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methyl-benzamide in the drug manufacture, method of treating acute attacks of chronic obstructive pulmonary disease, a drug for oralinjection comprising 3-[5-amino-4-(3-cyanobenzoyl)-pirasol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof are also proposed.EFFECT: treatment of acute attacks of chronic obstructive pulmonary disease.17 cl, 5 tbl, 1 ex
Water-based liquid composition with bromfenac possessing preservative effectiveness // 2625755
FIELD: chemistry.SUBSTANCE: invention represents the use of bromfenac or its salt to improve the preservative effectiveness of the water-based liquid composition, comprising (a) bromfenac or its salt and (b) benzalkonium chloride, and c) at least one agent selected from the group consisting of nonionic surfactant and water-soluble polymer. The invention also relates to a method of improving the preservative effectiveness of the aqueous solution described above, which comprises adding of bromfenac or its salt in an amount of 0.1 w/v % to the solution.EFFECT: invention enables to obtain a composition with imroved preservative activity, wherein there are low concentrations of benzalkonium chloride preserving agent.10 cl, 21 tbl, 4 ex

Bromelain extract with proteolytic activity to treat connective tissue diseases // 2625726
FIELD: medicine.SUBSTANCE: pharmaceutical composition comprising a proteolytic extract obtained from bromelain is used for treatment of connective tissue diseases. Thus, bromelain is obtained from pineapple stem. Proteolytic extract contains stem bromelain, ananain and jacalin-like lectin. The connective tissue disease is associated with excessive deposition of collagen, such as Dupuytren's disease and Peyronie's disease.EFFECT: efficiency and selectivity of action against type III collagen degradation in Dupuytren's chords; no damage for healthy connective tissue.16 cl, 13 dwg, 2 ex
ethod for spinal osteomyelitis treatment // 2625596
FIELD: medicine.SUBSTANCE: puncture needle is introduced under ultrasound supervision in the abscess cavity, the contents is taken for the study, a drainage system is installed, which is used for abscess cavity sanitation and drainage. Laboratory research of the abscess cavity content is performed dynamically. At that, the necessary amount of antiseptic solution is determined for introduction into the abscess cavity in liters/min based on: abscess cavity volume ratio Vcavity/l multiplied by a factor of 0.7. Sanitation is carried out to achieve abscess cavity abacillation by supplying of an antiseptic solution combined with active aspiration of an antiseptic solution and dispersive suspended necrotic masses from the abscess cavity. A sodium chloride solution saturated with ozone-oxygen mixture with a level of oxidation-reduction potential of not lower than 600 mVA is used as the antiseptic solution, which is maintained during the entire sanitation by providing continuous readjustment of sodium chloride solution saturation with ozone-oxygen mixture until the end of the procedure.EFFECT: method allows to increase the efficiency of pathological focus antiseptic treatmen, provide a reliable bactericidal effect.1 ex
ethod of correction of the age-related face skin changes // 2625548
FIELD: cosmetology.SUBSTANCE: method includes intradermal injection of the "Hyalual" preparation containing unstabilised hyaluronic acid and succinate. In the treated area, skin tension lines are marked and "Hyalual" 2.2% 1-2 ml is injected in small doses into the middle layer of the derma between the reference zones along the indicated tension lines by retrograde short-line technique, with the needle inserted into the skin at an angle of 30-45° to the middle or 1/3 length.EFFECT: increased effectiveness of correction of the age-related face skin changes by increasing the therapeutic effect of the Hyalual preparation by means of optimising the scheme and techniques of its injection.1 dwg
Pharmaceutical aerosol composition and method for pharmaceutical composition production // 2625504
FIELD: pharmacology.SUBSTANCE: pharmaceutical drug composition for treatment of wounds and other skin defects consists of 0.1-99.9% vinyl butyl polyether, 0.1-99.9% of low boiling aliphatic ester as a solvent, and a pharmaceutically acceptable carrier gas. Diethyl ether is used, in particular, as a low-boiling aliphatic ester.EFFECT: method for pharmaceutical composition preparation is based on vinyl butyl polyester dilution in low boiling aliphatic ether, sterile filtration and applicator filling under pressure, together with a carrier gas dose under conditions ensuring mixture sterility.10 cl, 4 ex, 2 tbl

Substituted diamino-carboxamide and diamino-carbonitrile pyrimidine derivatives, their compositions and methods of treatment using them // 2625309
FIELD: pharmacology.SUBSTANCE: in formula (I) , R1 and R2 independently represent unsubstituted C1-8alkyl; C1-8alkyl substituted with one or more halogen atoms, hydroxy, C1-3alkoxy, C1-3alkoxy, C1-3alkyl, halogenC1-3alkoxy or hydroxyC1-3alkyl; unsubstituted saturated 3-7-membered monocycloalkyl or 5-8-membered bicycloalkyl; substituted saturated 3-7-membered monocycloalkyl or 5-8-membered bicycloalkyl, wherein the substituents are selected from halogen, C1-6alkyl, hydroxy, oxo, C1-3alkoxy, C1-3alkoxyC1-3alkyl, halogenC1-3alkyl, halogenC1-3alkoxy, hydroxyC1-3alkyl, aminoC1-3alkyl, O-cyclopropyl, NH2, NH(C1-3)alkyl, N(C1-3alkyl)2, C(O)-C1-3alkyl, NHC(O)-C1-3alkyl, C(O) NH2, C(O) NHC1-3alkyl, C(O)N(C1-3alkyl)2 and NHSO2(C1-3alkyl) and pyrrolidine; unsubstituted C1-3alkyl-C3-6cycloalkyl; 4-6-membered nonaromatic monocyclic heterocyclyl, optionally N-substituted with group of C1-3alkyl-C(O) or optionally substituted with C1-3alkyl, oxo or hydroxy, wherein heteroatoms are selected from 1-2 oxygen atoms or 1 nitrogen atom, or dioxaspirodecanyl.EFFECT: compounds can be used for the treatment or prevention of fibrotic liver diseases or metabolic syndrome, which lead to the development of fibrotic liver diseases such as: nonalcoholic steatohepatitis, steatosis, cirrhosis, primary sclerosing cholangitis, primary biliary cirrhosis, hepatitis, hepatocellular carcinoma or liver fibrosis, connected with chronic or recurrent alcohol consumption, infection, liver transplantation or liver injury caused by taking drugs, and as well as for treatment or prevention of interstitial pulmonary fibrosis.67 cl, 3 tbl, 62 ex
ethod for personified photodynamic therapy of extensive cosmetic skin defects // 2625297
FIELD: cosmetology.SUBSTANCE: drug based on 5-aminolevulinic acid is applied on the entire face and / or head skin. After 1 hour after drug application on skin, fluorescence spectroscopy is carried out, determining the fluorescence intensity (FI), on the basis of which a dose of laser irradiation for PDT is chosen from the range of 5-45 J/cm2. The lower the FI, the smaller the dose of irradiation. PDT irradiation of the entire skin is carried out using laser radiation with a wavelength of 400-800 nm.EFFECT: method allows to increase the PDT efficiency of extensive cosmetic skin changes due to personified selection of the therapeutic dose of laser irradiation taking into account the quantitative measurement of accumulation level of 5-ALA of induced protoporphyrin IX by fluorescence spectroscopy method.4 dwg, 2 ex
ethod for adhesiogenesis stimulation in pleural cavity in case of polytraumas with predominant thoracic involvement // 2625002
FIELD: medicine.SUBSTANCE: invention concerns adhesionogenesis stimulation in the pleural cavity in case of polytraumas with predominant thoracic involvement. To do this, a 10% homogenized suspension of autologous adipose tissue in a physiological solution is injected pointwise into the pleural cavity into the ribs fracture region subpleurally, under the parietal pleura.EFFECT: method ensures pulmonary framework stabilisation and early fusion of ribs due to adhesiogenesis stimulation and adhesions formation in the pleural cavity.2 cl, 1 ex
 
2550874.
Up!